TMT, a new cancer drug, demonstrated strong results in phase 3 trials for advanced or recurrent endometrial cancer patients.

Patient preference is an important part of cancer treatment planning, but new research suggests that many women facing ...

The TroFuse-005 trial involved 776 patients with endometrial cancer whose disease worsened after receiving both platinum ...

Merck & Co. Inc. (NYSE:MRK) is one of the best low risk stocks to buy in 2026. On May 18, Merck announced that its pivotal ...

Patients with gynecologic cancers may soon hear about new advances in immunotherapy, antibody-drug conjugates (ADCs), vaccines and even cell therapies during the 2026 ASCO Annual Meeting. This year’s ...

Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug ...

A second opinion physician was held liable for an unnecessary hysterectomy despite a laboratory mix-up at the original facility.

Uterine cancer, often referred to as endometrial cancer, is the most common gynecological cancer in the United States. It forms in the uterus, which is the hollow, pear-shaped organ in the lower ...

“Endometrial cancer treatment generally has a high success rate, especially when the cancer is found early,” says John Wallbillich, MD, gynecologic oncologist at the Barbara Ann Karmanos Cancer ...

Although it is known that obesity increases the risk of endometrial cancer and is linked to higher mortality rates in the general population, the association between obesity and mortality among ...